OCMS Bio, LLC is an antibody engineering company that uses a breakthrough discovery technology to create best in class antibody drugs. Our most advanced program, OB2401, is an anti-RSV prophylactic proven in animal testing to outperform all existing alternatives. Other programs under current development target human metabolic diseases and rare diseases. OCMS Bio, LLC is headquartered in the United States, near Philadelphia, Pennsylvania. OCMS Canada is headquartered in Prince Edward Island and represents a new business with material ownership by OCMS Bio established with a significant stake in OB2401 and investment to advance the pre-clinical development of OB2401.